Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

Abstract

Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4%); HEP in 204 (40.2%) and NEU in 44 (8.7%). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2

References

  1. 1

    Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206–3214.

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077–2084.

    CAS  Article  PubMed  Google Scholar 

  3. 3

    Vecchi V, Arico M, Basso G, Ceci A, Madon E, Mandelli F et al. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies. Cancer 1993; 72: 2517–2524.

    CAS  Article  PubMed  Google Scholar 

  4. 4

    AIRTUM Working Group CCM AIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 37 (1 Suppl 1): 1–225.

  5. 5

    Gervasini G, Vagace JM . Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet 2012; 3: 249.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Stocco G, Franca R, Verzegnassi F, Londero M, Rabusin M, Decorti G . Pharmacogenomic approaches for tailored anti-leukemic therapy in children. Curr Med Chem 2012; 20: 2237–2253.

    Article  Google Scholar 

  7. 7

    Franca R, Rebora P, Basso G, Biondi A, Cazzaniga G, Crovella S et al. Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics 2012; 13: 1905–1916.

    CAS  Article  PubMed  Google Scholar 

  8. 8

    Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ . Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15: 1560–1566.

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Rizzari C, Putti MC, Colombini A, Casagranda S, Ferrari GM, Papayannidis C et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep 2014; 6: 5554.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011; 21: 679–686.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11

    Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN . Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology 2008; 47: 1156–1159.

    CAS  Article  PubMed  Google Scholar 

  12. 12

    Li L, Agarwal S, Elmquist WF . Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos. 2013; 41: 659–667.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13

    Bleyer WA, Dedrick RL . Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977; 61: 703–708.

    CAS  PubMed  Google Scholar 

  14. 14

    Ohta A, Sitkovsky M . Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916–920.

    CAS  Article  Google Scholar 

  15. 15

    Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151–4157.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16

    Heller T, Oellerich M, Armstrong VW, von Ahsen N . Rapid detection of ITPA 94C>A and IVS2+21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2+21A>C polymorphism on splicing efficiency. Clin Chem 2004; 50: 2182–2184.

    CAS  Article  PubMed  Google Scholar 

  17. 17

    Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009; 85: 164–172.

    CAS  Article  PubMed  Google Scholar 

  18. 18

    Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 2011; 71: 575–584.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19

    Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE 2012; 7: e45558.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20

    Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, Baba AA et al. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther 2012; 37: 237–241.

    CAS  Article  PubMed  Google Scholar 

  21. 21

    Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012; 21: 4793–4804.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22

    Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925–1929.

    CAS  Article  PubMed  Google Scholar 

  23. 23

    Soontornmalai A, Vlaming ML, Fritschy JM . Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006; 138: 159–169.

    CAS  Article  PubMed  Google Scholar 

  24. 24

    Kilic E, Spudich A, Kilic U, Rentsch KM, Vig R, Matter CM et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008; 131: 2679–2689.

    Article  PubMed  Google Scholar 

  25. 25

    Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB . PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012; 22: 555–558.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26

    Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 240–244.

    CAS  Article  PubMed  Google Scholar 

  27. 27

    Moore AS, Norris R, Price G, Nguyen T, Ni M, George R et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 2011; 47: 875–882.

    Article  PubMed  Google Scholar 

  28. 28

    Davies SM, Borowitz MJ, Rosner GL, Ritz K, Devidas M, Winick N et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 2984–2990.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29

    Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA . NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol 2008; 168: 1221–1232.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30

    van Rossum EF, Koper JW, van den Beld AW, Uitterlinden AG, Arp P, Ester W et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 2003; 59: 585–592.

    CAS  Article  Google Scholar 

  31. 31

    Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144–151.

    CAS  PubMed  Google Scholar 

  32. 32

    Cuzzoni E, De Iudicibus S, Bartoli F, Ventura A, Decorti G . Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br J Clin Pharmacol 2012; 73: 651–655.

    CAS  Article  PubMed  Google Scholar 

  33. 33

    Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G et al. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer 2009; 53: 984–991.

    Article  PubMed  Google Scholar 

  34. 34

    Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M . Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 2002; 16: 1437–1442.

    CAS  Article  PubMed  Google Scholar 

  35. 35

    French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 4496–4499.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36

    Stocco G, Crews KR, Evans WE . Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 2012; 9: 23–37.

    Article  Google Scholar 

  37. 37

    Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009; 19: 935–944.

    CAS  Article  PubMed  Google Scholar 

  38. 38

    Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A et al. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2847–2858.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39

    Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008; 68: 3161–3168.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40

    Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008; 68: 10178–10186.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

PR was partially supported by the grant MIUR-SIR 2014 (RBSI14LOVD). We thank AGMEN (Associazione Genitori Malati Emopatici Neoplastici)-Friuli Venezia Giulia (Italy) and IRCCS Burlo Garofolo in Trieste (Italy) for supporting the pharmacogenetic project.

Author contributions

RF was the principal investigator and contributed to study design, genetic analysis, data interpretation and paper writing; PR is responsible for the study design and statistical analysis; NB recruited patients and collected the clinical data; FF and VC discussed results and revised the manuscript; AB, AC, CM, MZ, RP, FP, GB, MCP and FL recruited patients and collected the clinical data; PD contributed for genetic analysis; MGV and GD discussed results and revised the manuscript; MR contributed to study design, co-ordinated the clinical part, discussed results and revised the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to R Franca.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Franca, R., Rebora, P., Bertorello, N. et al. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J 17, 4–10 (2017). https://doi.org/10.1038/tpj.2015.83

Download citation

Further reading

Search

Quick links